rabeprazole
rabeprazole: sourced relationships with 3 companies · 6 clinical trials tracked · 3 FDA decisions.
rabeprazole evidence translation
What we can confirm
3 FDA records · 6 tracked trials
What it means
What to watch
Prepared research question
What is verified about rabeprazole, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 3 study sponsors
Dated Pipeline Records (3)
| Company | Dated record stage |
|---|---|
| AYTU BIOPHARMA, INC (AYTU) Reported 2013-03-26 · Current development: unknownSource | Approved |
| LANNETT CO INC (LCI) Reported 2013-11-08 · Current development: unknownSource | Approved |
| DR REDDYS LABORATORIES LTD (RDY) Reported 2013-11-08 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (6)
An Open-Label, Randomized, Four-Period, Six-Sequence Phase I Study to Evaluate the Effect of Food and Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of HMPL-760 Capsules in Healthy Participants
Primary endpoint: AUC 0-last
A PHASE 1, OPEN-LABEL, RANDOMIZED, 5-PERIOD, 6-SEQUENCE, CROSSOVER STUDY TO COMPARE THE SINGLE-DOSE PHARMACOKINETICS OF ONE IMMEDIATE RELEASE AND TWO MODIFIED-RELEASE FORMULATIONS OF PF-08049820 ADMINISTERED ORALLY UNDER FASTED AND FED CONDITIONS (PART A), AND A FIXED SEQUENCE STUDY TO ASSESS THE EFFECT OF RABEPRAZOLE ON THE PHARMACOKINETICS OF PF-08049820 (PART B), IN HEALTHY ADULTS
Primary endpoint: Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)
A Phase 1, Open-label, Randomized, Four-way Crossover Study to Assess the Relative Bioavailability of Two Phase 3 LY4100511 (DC-853) Tablet Formulations Compared With the Phase 2 LY4100511(DC-853) Tablet Formulation, With and Without a Proton Pump Inhibitor in Healthy Participants
Primary endpoint: Pharmacokinetic (PK): Area Under the Concentration Curve from 0 to Infinity (AUC0-∞) of LY4100511 (DC-853)
A Modular Phase I, Open-label Study to Assess the Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies
Primary endpoint: Module 1: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf) of digoxin, furosemide, metformin and rosuvastatin when dosed alone and in combination with saruparib
A Phase 1 Clinical Trial in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of TERN-701, the Effects of Food, Acid-Reducing Agents, and Drug-Drug Interactions, and the Relative Bioavailability of New Tablet Formulations of TERN-701
Primary endpoint: Number of Participants Who Experience a Treatment Emergent Adverse Event (AE)
A Phase 1/2 Study of BMS-986408 Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Primary endpoint: Number of Participants With Dose Limiting Toxicities (DLTs)
FDA Decisions3 records
Frequently asked questions
Which companies have sourced relationships with rabeprazole?
rabeprazole has dated SEC/FDA relationship records for AYTU BIOPHARMA, INC, LANNETT CO INC, DR REDDYS LABORATORIES LTD.
How many clinical trials involve rabeprazole?
BioSniper tracks 6 clinical trials involving rabeprazole.
What is rabeprazole's latest FDA decision?
The most recent tracked FDA decision for rabeprazole is Approval, dated November 8, 2013.